To validate the prognostic ability of the immunocyte fraction, we used CD8 mRNA expression (461 cases in TCGA) and CD8+ expressing T cells (216 cases in TCGA) in CRC patients for the time-dependent ROC curve and the analysis of Kaplan–Meier survival estimates. The gene discussed is CD8A; the disease is colorectal carcinoma.